04 Malignant Skin Lesions

Wong sl coit dg role of surgery in patients with

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453, 1999 56. McMasters KM: The Sunbelt Melanoma Trial. Ann Surg Oncol 8:41S, 2001 57. Wong SL, Coit DG: Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 16:155, 2004 58. Benckhuijsen C, Kroon BB, van Geel AN, et al: Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14:157, 1988 59. Lingam MK, Byrne DS, Aitchison T, et al: A single center’s 10-year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 32A:1668, 1996 60. Vrouenraets BC, Nieweg OE, Kroon BB: Thirtyfive years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83:1319, 1996 61. Grunhagen DJ, Brunstein F, Graveland WJ, et al: One hundred consecutive isolated limb perfusions with TNF-alpha and Melphalan in melanoma 66. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7, 1996 67. Wheatley K, Ives N, Hancock B, et al: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241, 2003 68. Tafra L, Dale PS, Wanek LA, et al: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110:119, 1995 69. Ollila DW, Essner R, Wanek LA, et al: Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131:975, 1996 70. Finkelstein SE, Carrasquillo JA, Hoffman JM, et al: A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 11:731, 2004 71. Miner TJ, Jaques DP, Shriver CD: A prospective evaluation of patients undergoing surgery for the palliation of an advanced malignancy. Ann Surg Oncol 9:696, 2002 72. Cohen GL, Falkson CI: Current treatment options for malignant melanoma. Drugs 55:791, 1998 73. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158, 2000 [erratum, J Clin Oncol 18:2351, 2000] 74. Morton DL, Foshag IJ, Hoon DS, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463, 1992 75. Butterfield LH, Ribas A, Dissette VB, et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998, 2003 76. Soiffer R, Hodi FS, Haluska F, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343, 2003 77. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nature Med 10:909, 2004 78. Immunotherapy.Wikipedia,The Free Encyclopedia. http://en.wikipedia.org/wiki/Immunotherapy, accessed August 2, 2006 79. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907, 1994 80. Atkins MB, Kunzel L, Sznol M, et al: High-dose recombinant IL-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6S:11, 2000 81. Dudley ME, Wunderlich J, Nishimura MI, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363, 2001 82. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850, 2002 83. Hughes MS,Yu YY, Dudley ME, et al: Transfer of a TCR gene derived from a patient with marked antitumor response conveys highly active T cell effector functions. Hum Gene Ther 16:457, 2005 84. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193, 1995 85. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635, 2001 Acknowledgment Figures 5 through 8 Susan E. Brust, C.M.I....
View Full Document

This note was uploaded on 03/21/2011 for the course ONC 01 taught by Professor Dzodic during the Spring '11 term at Multimedia University, Cyberjaya.

Ask a homework question - tutors are online